Neuroscience

Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease

Data demonstrates improvement in cognitive function in GBA1 Parkinson’s disease model in addition to reversal of motor function deficitsBETHESDA, Md.,…

5 months ago

INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease Trial

The planned interim analysis confirms the accuracy of the sample size calculations and statistical power for EMACC, the primary endpoint.…

5 months ago

STALICLA publishes pioneering phase 1b data on precision treatment for autism spectrum disorder in Biomedicines

Press Release STALICLA’s precision psychiatry study highlights strong EEG-based target engagement of STP1 treatment in defined subgroup of patients with…

5 months ago

Neurophet to present brain stimulation simulation study at OHBM 2024

- Presents a poster identifying tDCS effects for patients with AD and cognitively normal people - Showcases brain imaging treatment planning…

5 months ago

AMSBIO and Bioz Combine Efforts to Empower the Scientific Community With Citation Data

PALO ALTO, CA / ACCESSWIRE / June 26, 2024 / Bioz, Inc., a pioneer in AI-driven research solutions, is delighted…

5 months ago

Linus Health Introduces Person-Centered Approach to Establish Clinically Meaningful Benefits and Personalized Brain Health Care

Scalable, systematic and automated process captures and monitors metrics based on patients' treatment priorities for managing Alzheimer's disease and related dementias…

5 months ago

Zeto Announces Winners of Clinical Trial Sponsorship Program

SANTA CLARA, Calif., June 25, 2024 /PRNewswire/ -- Zeto, Inc., an award-winning medical technology firm, is proud to announce the…

5 months ago

Roche’s OCREVUS subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary progressive multiple sclerosis

OCREVUS subcutaneous (SC) injection offers a new, 10-minute administration of OCREVUS with comparable efficacy and safety to intravenous infusion (IV)…

5 months ago